Public–private partnerships in trust-based public health social networking: Connecting organizations for regional disease surveillance (CORDS)

We describe a new trust-based global health security initiative known as CORDS: Connecting Organizations for Regional Disease Surveillance. Initiated and managed by the Nuclear Threat Initiative with support of The Rockefeller Foundation, Fondation Mé…


New approaches to global health governance: The evolution to public–private partnerships

Global health issues that transcend geopolitical borders are altering the nature of global health governance. Sovereign nations are more connected than ever and increasingly exposed to trans-border health risks. Traditional global health governance may…


Public–private partnerships in global health

This issue of the Journal of Commercial Biotechnology includes the papers from the seventh Annual San Diego Health Policy Conference, ‘Public–Private Partnerships in Global Health’, held on 25 March 2011. The San Diego Heath Policy Conference is …


Journal of Commercial Biotechnology — August 2011 issue now available

The August 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper: Volume 17, Issue 3 Regional biotechnology – The EU biocluster study Bernhard Zechendorf Analyzing United States Prescribing Information to gain insight into FDA-sponsor discussions Iraj Daizadeh The United States Prescribing […]


Drug Patents Expiring in August 2011

Drug Patent Expirations in August 2011 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ULTRACET Ortho Mcneil Janssen acetaminophen; tramadol hydrochloride RE39221 Aug 9, 2011 CIPRO Bayer Hlthcare ciprofloxacin hydrochloride 5,286,754*PED Aug 15, 2011 MEGACE Bristol Myers Squibb megestrol acetate 5,338,732 Aug 16, 2011 NEORAL Novartis cyclosporine 5,342,625 […]


CNS Investment Opportunity

An early-stage CNS therapeutic company on whose board I sit is looking for investments in the UK or the United States. They describe their focus as “development of novel CNS assets that span from early development to human clinical trial stages.” If you would like to learn more, please let me know using the contact […]


What is the best approach to enter the biotechnology business

An interesting thread on the topic of educational paths to enter the biotechnology industry has popped up in the Journal of Commercial Biotechnology Linkedin group. Are you intrigued? Do you have any guidance? Hop over and join the discussion. Check out the Journal of Commercial Biotechnology and my Biotechnology Books for more information on the […]


Building Biotechnology in Turkey

The Turkish response to the innovation score I generated for them in the Scientific American Worldview Scorecard was pretty clear. They interpret their low score — 39th out of 48 countries measured — as an indication that they continue to ‘miss the biotech train.’ The primary reasons for Turkey’s low score are: Relatively weak intellectual […]


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: